In Vitro Diagnostics IVD丨Research Report

Core Summary:
Market Overview:

Conceptual Analysis: In vitro diagnostics (IVD) refers to the in vitro testing of samples (blood, body fluids, tissues, etc.) from the human body in order to obtain clinical diagnostic information and diagnose diseases or body functions. Known as the "doctor's eyes", it is an important component of modern laboratory medicine.

Category sorting: According to the testing method or technology, IVD products can be divided into five main categories: immunodiagnostic, biochemical diagnostic, molecular diagnostic, blood diagnostic, and microbiological diagnostic. According to the usage scenario, IVD products can be categorized into POCT and Lab Lab.

Market Size: The global IVD industry size of $97 billion in 2022 is expected to grow at a CAGR of 11.9% over the next four years, and will exceed $120 billion in 2026.

Hot Tracks.

Chemiluminescence: chemiluminescence is currently the most advanced technical means in immunodiagnosis. Applications include tumor markers, nail function, infectious diseases, hormones, cardiac markers, etc. The global chemiluminescence market size will be approximately $14.7 billion in 2022, accounting for 33.3% of the immunodiagnostic market.

POCT: POCT is mainly used in blood glucose testing, blood gas electrolytes, cardiovascular testing, infectious diseases, pregnancy testing and other tests (including routine blood, etc.). 2022 global POCT market size of $ 36.7 billion, and will face a pullback due to the epidemic factors in 2023, and then continue to rise at a growth rate of 15% -20%.

PCR: PCR polymerase chain reaction technology is the most widely used technology in molecular diagnostics. Nowadays, it is widely used in infectious diseases, oncology, genetic diseases, etc. The global molecular diagnostics market reached $18.4 billion in 2022 and is expected to reach $37.5 billion by 2026. 

Collective procurement winds up:

Collective procurement reasons: after the separation of technology and consumption, to determine the final charges, is the in vitro diagnostic reagent collection price of high and low. Therefore, the IVD collection undertakes the two major tasks of easing the pressure of medical insurance and standardizing the market order.

Existing difficulties: it is difficult to ensure the consistency of the detection system of each manufacturer, which will have a great adverse effect on clinical judgment; chemiluminescence instruments and reagents are mostly strong binding relationship, if forced to collect, hospitals will cause large cost expenditure.

Changes and breakthroughs: Competition pattern, the performance of the manufacturers with the collection of winning the bidding situation shows a strong correlation. In terms of business model, centralized procurement allows medical institutions to redistribute costs with manufacturers and agents to be controlled and cut. The main ways for enterprises to break the game include: moving the application market to the C-end, increasing the importance of the whole process of service, improving the bargaining power of raw materials by laying out the upstream, controlling the distribution of costs with agents, and exploring overseas market opportunities.

Trend Insight.

Developing countries' IVD market is characterized by small base and high growth rate, which will become the main direction for domestic IVD manufacturers to go overseas in the future.

TLA has become an important cornerstone for IVD automation, and domestic TLA companies are expected to usher in new development opportunities with high cost performance and strong compatibility.

IVD manufacturers, medical institutions, pharmaceutical companies, Internet companies, communications companies, universities and other industrial alliances will accelerate the realization of core technology breakthroughs and service levels.

IVD Market Overview

Definition of IVD

IVD is a medical testing method that plays an important role in modern medicine

In vitro diagnostics (IVD) is a medical testing method that tests samples (blood, body fluids, tissues, etc.) from the human body outside the body to obtain clinical diagnostic information and to diagnose diseases or body functions. Through the reaction between the IVD reagent and the human sample, a qualitative or quantitative diagnosis can be given and compared with normal values to determine the physiological state of the patient. In vitro diagnostics in the medical field is known as the "doctor's eyes", is an important part of modern laboratory medicine, in the clinical application of disease prevention, preliminary diagnosis, treatment program selection, efficacy evaluation of the whole process of disease treatment, can provide doctors with a large number of useful clinical diagnostic information, more and more become an important part of the diagnosis and treatment of human diseases, It can provide doctors with a large amount of useful clinical diagnostic information, and has increasingly become an important part of the diagnosis and treatment of human diseases, and plays an important role in the diagnosis of modern medical diseases.

Point ① Intercom: POCT's convenient and efficient technology can optimize the traditional testing process.

POCT has two key elements: spatially, in the patient's side of the test, without the need for specialized laboratories, i.e., "bedside test"; time, high detection efficiency, short time to results, can be "instant test". Unlike traditional diagnostic samples need to be transported, pre-processing, organization, labeling, recording, distribution and other complex processes, POCT streamlines the testing process of many steps, leaving only the core of the "sample collection-sample analysis-quality control-interpretation of the report" key steps.

Point ➋ Outshun:Multiple factors bring POCT demand surge
 Basic disease detection scenarios increase. a. Epidemic disease prevention and control testing: since the epidemic, the domestic new crown test is mainly nucleic acid test, therefore, the POCT product is not as favorable as the molecular diagnostics, the source of its sales performance is mainly overseas. But as China's epidemic prevention into the next stage, POCT kits are also expected to be more "export to domestic sales to release the domestic growth potential. b. Home daily monitoring needs: with the increase in diabetes / hypertension and other chronic diseases, POCT has become the most preferred choice of patients with chronic diseases home self-testing garment factory. c. The need to improve the quality of life of patients with chronic diseases. d. The need to improve the quality of life of patients with chronic diseases. e. The need to improve the quality of life of patients with chronic diseases.
 Graded diagnosis and treatment, medical resources sinking to promote the rapid development of the industry. With the rapid advancement of graded diagnosis and treatment in recent years, primary medical institutions have taken on more testing tasks POCT is convenient to operate, does not require supporting large testing instruments, so the test price is lower, can echo the needs of primary medical institutions in terms of cost-effective. Medical model change. Treatment to the integration of prevention, health care, treatment and rehabilitation; medicine to biological, psychological and social changes; hospital to out-of-hospital changes. Construction of the "five centers". Starting in 2017, the state has invested in the construction of five major centers for chest pain, stroke, trauma, critical maternity, critical children and neonates. The construction of these centers focusing on critical care is an important opportunity to promote the rapid release of POCT equipment for cardiovascular, cerebrovascular, and infection categories.

Review of China's IVD Industry

After nearly 40 years of development, China's IVD industry is in the stage of extensive application.

With the increasing acceptance of IVD test methods and products by the public and the gradual enhancement of the government's regulation of the market, China's IVD industry has gone through four major phases, namely, germination, exploration and standardization, high-speed development, and upgrading and substitution, and is now in the stage of wide application, with a promising trend of long-term development.

Application of IVD products

IVD products have a wide range of applications, covering the whole scenario from routine checkups to critical illnesses, and from individuals to medical institutions.

IVD products have a wide range of applications, not only can they be used to diagnose various diseases, but also can play an important role in life science research, sports medicine, environmental monitoring, food safety and other fields. Returning to the medical field, IVD products can usually be categorized in two different ways based on the type of disease and the type of end-user. Based on diseases, IVD products can cover a wide range of conditions from routine checkups to critical illnesses, including routine checkups and chronic diseases, infectious diseases, pregnancy, genetic diseases, tumors, and so on. Based on end-users, IVD products can cover a wide range of scenarios from individuals to healthcare institutions, including individuals, non-profit organizations (e.g., CDC, blood stations, colleges, etc.) and healthcare institutions (mainly hospitals and laboratories). Comprehensively speaking, IVD products radiate all stages of the clinical process, running through the whole process of disease treatment, such as initial diagnosis, choice of treatment plan, evaluation of effectiveness, confirmation of diagnosis and cure, etc. With the deepening of research and technological advances, there will be more possibilities for the application of IVD products in the future.

Classification by Detection Principle

Immunodiagnostic and molecular diagnostic technologies are fast changing, widely used and widely noticed by the market

According to the aforementioned, IVD can be broadly categorized into five types according to the detection principle. Among them, biochemical diagnostics technology is more mature, with wide clinical application; immunodiagnostics market accounts for the highest proportion, and chemiluminescence will lead a new round of technological innovation and volume growth in the future; molecular diagnostics has been growing faster in recent years, mainly based on second-generation gene sequencing, which has great space for development in the field of early tumor screening; microbiological diagnostics and blood diagnostics account for a lower proportion, and the space for growth is limited.

Global IVD Market Size: By Assay Principle

Immunodiagnostics is currently the largest segment of the IVD market, molecular diagnostics to maintain steady growth

Overall, the global IVD market size is growing at a promising pace, and has now reached $97 billion. Although the IVD market will face a certain degree of retraction in 2023 with the basic end of the new crown epidemic and the full liberalization of epidemic prevention and control, the IVD market is still expected to exceed $100 billion in 2025. Breakdown, immune diagnosis can be applied to infectious diseases, endocrine, tumor, drug testing and other fields, is currently the largest segment in the IVD market, accounting for 45.5%; in addition, molecular diagnostics in the PCR technology under the auspices of the will continue to maintain high growth, is expected to be about 5 years with immune diagnostic show "rivalry The situation of "rivalry" with immunodiagnostics is expected in about five years.

Categorized by usage scenarios

Lab and POCT specialize in solving different needs and pain points respectively

IVD products can be categorized into Lab and POCT according to usage scenarios. Commonly speaking, Lab is a test performed in the laboratory and adopts strict quality management for the whole test, while POCT is a rapid diagnostic test performed beside the patient. Comparison, POCT products are more flexible testing locations, no geographical restrictions, can be tested directly around the test object and does not require professional testing personnel to operate, you can save a lot of cumbersome process, direct and rapid to get reliable results for the doctor to further diagnosis and treatment to win the noble time, a significant reduction in the delivery of the test and occupies the time of the health care personnel and patient hospitalization time and thus reduce the hospital's overall Costs of hospitals can be reduced. However, the accuracy of POCT still has some room for improvement compared with Lab, and improving the accuracy will be the main focus of POCT in the future.

Global IVD Market Size: By Usage Scenario

POCT is growing rapidly, at a faster rate than the overall IVD market

POCT has been popularized as a new type of testing product since the 1910s and has grown rapidly due to its convenience and price-friendliness. Its market size has reached nearly USD 10 billion by 2022, with market share rising from 29.0% in 2017 to 37.8% in 2022. However, it should be clear that POCT and traditional laboratory Lab testing is complementary to each other, the emergence of POCT is a strong complement to the defects of traditional testing technology, does not mean that it will squeeze the market space of the laboratory, a lot of more stringent requirements for the detection of the environment and testing accuracy of the test project still need to be carried out in Lab, the short term POCT can not be realized technology replacement, so Lab will still be in the Lab will still maintain a relatively stable growth rate in the future.

Positioning of CLIA in immunodiagnostics

Chemiluminescence is currently the most advanced technology in immunodiagnosis.

Immunodiagnosis is a series of tests designed to measure antigens, antibodies, immune cells and cytokines secreted by them by applying immunological theories. With the interpenetration of disciplines, the scope of immunology has been expanding, and new immunological testing methods are emerging. In recent years, the domestic clinical application of chemiluminescence detection technology, chemiluminescence immunoassay is a combination of highly sensitive chemiluminescence measurement technology and highly specific immune response for the detection of various antigens, semi-antigens, antibodies, hormones, etc. It is the latest immunoassay technology following the development of radioimmunoassay, enzyme immunoassay, fluorescent immunoassay, and time-resolved fluorescent immunoassay. It has the advantages of high specificity, stable reagent, high automation and large-scale detection, etc. It has been rapidly promoted in clinical application and is gradually replacing other qualitative methods to become the mainstream diagnostic technology in the field of immunoassay, occupying nearly 60% of the market share.

Principles and Applications of CLIA

Chemiluminescence can be categorized into direct, enzymatic and electroluminescence according to the principle and characteristics of luminescence.

Chemiluminescence usually includes direct chemiluminescence, enzymatic chemiluminescence and electrochemiluminescence. The application items are more extensive, including tumor markers, nail function, infectious diseases, hormones, cardiac markers and so on. Direct chemiluminescence refers to the direct labeling of antigens or antibodies with chemicals, such as isoluminol, acridine ester, etc. The chemiluminescence is completed within seconds and is independent of changes in ambient temperature. Enzymatic chemiluminescence refers to some chemical reactions, the excited state product itself does not emit light or very weak light, but by adding luminescent substrate can lead to luminescence, luminescence intensity for antigen or antibody detection, susceptible to ambient temperature. Electrochemiluminescence is a specific chemiluminescent reaction initiated electrochemically on the surface of an electrode, where the antibody is directly labeled by ruthenium terpyridine, and the label directly emits light during the reaction.

IVD Hot Segments Explained

Immunodiagnostics and CLIA Global Market Size

Immunodiagnostics market size of $44.1 billion in 2022, chemiluminescence accounted for nearly 60% after the epidemic

According to the estimation of Avery Consulting, the global immunodiagnostic market size reached $44.1 billion in 2022, and will face a pullback in 2023, and then continue to rise at a growth rate of 10%. In 2022, the chemiluminescence market size of about $14.7 billion, accounting for 33.3%, and then with the continuous development of chemiluminescence technology and application scenarios greatly expanded, as well as the LFIA market size of the fall, its share will rise year by year, is expected to chemiluminescence in 2026 accounted for about 70%, will become the absolute main force of immunodiagnostics.

Development background and core advantages of POCT

Internal and external smooth: POCT's own rapid and economic characteristics respond to the testing needs of the general environment.

POCT Global Market Size

POCT market size of $36.7 billion in 2022, expected to exceed $40 billion in 2026

According to Avery Consulting's estimation, the global POCT market will reach $36.7 billion in 2022, and will face a pullback in 2023 due to the epidemic factor, and then continue to rise at a growth rate of 15%-20%. The main reasons for maintaining this growth rate include: a. Developing countries are paying more attention to primary healthcare, and POCT can complete the test efficiently at a lower cost; b. Public healthcare awareness is increasing, and the home self-testing market is bringing more development opportunities, such as self-testing of glucose for diabetic patients, and self-testing of HCG for women of childbearing age.

Positioning of PCR in molecular diagnostics

PCR is the most widely used technique in molecular diagnosis.

Molecular diagnostic technology refers to the use of DNA and RNA as diagnostic materials, molecular biology technology through the detection of the presence of genes, defects or abnormal expression, so as to make a diagnosis of the state of the human body and disease technology. It is a general term for technologies based on molecular level detection, of which PCR polymerase chain reaction technology is the most widely used technology in molecular diagnostic technology. At present, the second generation of real-time fluorescence PCR is the dominant technology in PCR, which needs to be carried out in a closed system, reducing the probability of experimental contamination, and can monitor the amount of amplification products through the intensity of fluorescence signals for quantitative detection, which can be used for the diagnosis of various types of hepatitis, AIDS, avian influenza, tuberculosis, venereal diseases, and other infectious diseases and evaluation of the efficacy of the disease; eugenics testing for thalassemia, hemophilia, and fetal anomalies; Tumor markers and tumor gene testing can be used for tumor diagnosis; genetic testing can be used for genetic disease diagnosis, etc., which is the most widely used in clinical application at present.

Technical development history and application of PCR

Second-generation qPCR is the current mainstream technology, and third-generation dPCR is under rapid development.

Since its introduction in the 1980s, PCR technology has gone through several technological changes and is now widely used in infectious diseases, tumors, genetic diseases and other medical fields. The first generation of PCR technology can only obtain qualitative results after amplification. Until the 1990s, along with the development of biofluorescence technology, real-time fluorescence quantitative PCR came into being and has become the mainstream technology for quantitative nucleic acid detection, which is used until now. However, with the improvement of detection requirements, qPCR gradually failed to meet the clinical requirements of some ultra-high sensitivity and precision testing. At the end of the 20th century, Vogelstein et al. proposed the concept of digital PCR, in which a sample is fully diluted and separate, parallel PCR reactions are performed in each reaction unit to realize absolute quantification and detection of rare alleles. Currently, digital PCR technology is still under development, and it is expected to be equal to the current fluorescent quantitative PCR when the technology matures, or even realize gradual substitution.

Global Market Size of Molecular Diagnostics

Molecular Diagnostics Market Size of $18.4 Billion in 2022, Expected to Reach $37.5 Billion by 2026

According to the estimation of Avery Consulting, the global molecular diagnostics market size grew from $10.2 billion in 2018 to $18.4 billion in 2022, and with the popularization of molecular diagnostic technologies in the fields of infectious diseases, cancer, and genetic diseases, as well as the development of three-generation digital PCR, the market will continue to maintain a higher growth rate, and it is expected to reach $37.5 billion in 2026, and the CAGR of 2023-2026 will reach 19.8%. growth rate of 19.8% from 2023 to 2026.

Mainstream Procurement Mode of IVD

Single procurement and centralized procurement in parallel, of which the effect of centralized volume purchase is most obvious

At present, the mainstream procurement mode of IVD in China can be broadly divided into two categories: single procurement and centralized procurement. Single procurement is generally divided into four types according to the procurement body: hospital procurement, government procurement, military procurement and CDC procurement, of which hospital procurement is the current mainstream mode, which will be derived from the Sunshine Procurement Platform network this way. Centralized procurement can be divided into centralized network, centralized bidding, centralized volume purchasing three modes, three comparisons, centralized network is the softest, accordingly difficult to play a very good effect of price reductions; centralized bidding with the attributes and characteristics of the IVD reagents match lower; volume purchasing is currently the largest reduction, but also the main procurement mode used in recent regions, the most far-reaching impact on the industry.

Challenges and Opportunities of IVD Collective Procurement 

Strategic Value and Significance of IVD Collective Procurement

Reducing the cost of medical insurance and standardizing the market order

In recent years, with the implementation and advancement of various national price control policies, the prices of some drugs and high-value medical consumables have been controlled, while at the same time, the problem of irrational revenue structure of hospital operation has also appeared. According to HIA's "China's first public hospital cost report", the cost of medical testing department's yield is as high as 89%, far exceeding the average value of 36.57%, ranking first. The cost of a test program mainly consists of technical service costs and reagent consumption costs of two parts, the traditional charges in the technology consumption confusion, it is difficult to find the entry point for price reduction, technology consumption separation can be achieved one by one to break through the effect of which [consume] need to use the collective purchasing to achieve a significant price reduction. However, in the long run, the collection to the industry is far more than just a price cut, in the hospital admission price drop, production enterprises into the shortlist, the medical anti-corruption encoded in the background, from the collection of raw materials from the upstream to the production enterprises, distribution companies and a series of problems will be revealed, the industry's integration and business environment will begin to purify.

Price regulation policies in IVD field in recent years

Many provinces have issued documents one after another, and the IVD price regulation policy is advancing rapidly

Starting from 2019, Jilin, Sichuan, Anhui and other provinces have issued documents to explore the implementation of IVD reagent sunshine listing and centralized procurement, and many of these provinces have also explicitly encouraged the implementation of banded purchasing for IVDs, which indicates that a large-scale price rectification in the field of IVD is about to unfold. Among them, Anhui Province clearly put forward "part of the clinical use of larger, higher procurement amount, clinical use of more mature, more fully competitive clinical testing reagents into the scope of procurement; chemiluminescent reagents 4 categories (tumor-related antigens, infectious diseases, cardiomyopathies, hormones, calcitoninogen detection) 23 small products to carry out targeted collective procurement. To belong to the "Notice" procurement product range, not included in the negotiation of bargaining similar products, the price linkage to not higher than the negotiation of the successful product price level; do not participate in the negotiation of bargaining, negotiation unsuccessful and do not confirm the bandwidth linkage price of the product, adjusted to the record transaction directory." This has laid the policy foundation for the subsequent smooth implementation of collective purchasing in Anhui Province, and has created a new template for banded purchasing in various provinces.

Difficulties and Challenges of IVD Collective Procurement at Present

Detection consistency is difficult to ensure, strong binding mechanism easily leads to secondary costs

In the early stage of IVD procurement, biochemical diagnostics are mainly used for the following reasons: a. biochemical methodology has the special characteristics of platform sharing; b. biochemical diagnostics are relatively the earliest developed and more mature. With the collection and procurement system and the improvement of the relevant process, the current stage of collection and procurement focus is gradually shifted from biochemical diagnostics to chemiluminescence, however, all kinds of new difficulties and new challenges also come one after another. First of all, the consistency of the detection system of each manufacturer is difficult to be guaranteed, more commonly known as the same reagent through the test of different manufacturers may show different results, this difference will have a great adverse effect on clinical judgment. Secondly, chemiluminescence instruments and reagents are mostly strong binding relationship, the collection of one or several kinds of reagents basically can not match all the instruments in the region, if the collection is forced, hospitals need to buy the same collection of reagents to match the instrument again, which will result in a large amount of cost expenditure.

The impact of IVD procurement on the competitive landscape

Taking Anhui as an example, the performance of each manufacturer is strongly correlated with the winning of bids.

In August 2021, Anhui piloted the provincial chemiluminescent reagent volume purchasing, firing the first shot of the routine substantial IVD reagent volume purchasing. The scope of this procurement mainly includes tumor markers, thyroid, infectious diseases, myocardial markers and calcitoninogen, a total of 23 reagent items. According to the negotiation and bargaining rules, the top five enterprises with market share are shortlisted to participate in the negotiation, and similar products not included in the negotiation and bargaining scope will be linked to price reduction according to certain rules. Among the domestic manufacturers, Meiry and New Industry have shown outstanding performance, winning 14 items each, while Siemens and Abbott among the four leading overseas manufacturers have won 12 and 18 items respectively. Combined with the business data of each manufacturer from 2011-2022, the growth and coverage of the chemiluminescence business of Myers, New Industries, Siemens, and Abbott in Anhui Province have increased significantly, while Roche and Beckman, which did not win the bid, have seen their revenues decline significantly. Enough to illustrate the correlation between the performance of the collection and the performance of the manufacturers, in this context, the domestic leader may be able to obtain more opportunities and market space.

Impact of IVD Collective Purchasing on Traditional Business Models

Fees available for redistribution between medical institutions and vendors and agents are controlled and cut

According to the ratio of technology-consumption separation (9:1) of Jiangxi Medical Insurance Bureau, if a project charges 10 RMB, the technical service fee is about 9 RMB and the consumables cost is about 1 RMB. In the traditional business model, the Medical Insurance Bureau will test the total cost of $ 10 unified payment to the medical institutions, although in fact there is a 9:1 ratio, but the medical institutions and agents in the actual distribution process may not strictly follow this ratio, so the traditional model of the profitability of the node can be seen. After the implementation of the separation of technology and consumption, the Medical Insurance Bureau to pay medical institutions and agents, respectively, the service cost of 9 yuan and reagent cost of 1 yuan, agents and manufacturers can access the cost of 10 yuan plummeted to 1 yuan, the traditional business model is difficult to sustain, forcing manufacturers and agents must seek a new point of profitability, i.e., the manufacturers need to think about how to reduce costs and increase efficiency within the existing business model system, the agent needs to think about the conversion process in the high gross margin to the low gross margin, the profit point of the traditional model is revealed. Low gross profit conversion process, how to do a good job of terminal customer relations, linking more application scenarios.

Under the background of collective procurement, the midstream manufacturers' breakthrough exploration

Courageous and resourceful: Courageous to explore new markets and new scenarios, and resourceful to do fine services and control costs.

According to the previous article, IVD midstream vendors are unable to follow the traditional business model under the background of centralized procurement, and are in urgent need of "transformation and upgrading". Comprehensive industry status quo, Ai Rui believes that enterprises should first rivet the target market and positioning according to their own situation, and then carry out the next stage of the path to explore. There are mainly the following ways for reference: a. Move the application market forward, do a good job of home testing product innovation and promotion; b. Do a wide range of services to do fine, IVD product integration, increase the importance of the whole process of service; c. Grasp on the control of the lower part of the layout of the upper reaches of the raw materials to enhance the bargaining power, and at the same time control and the distribution of costs between the agents; d. Avoid the white-hot competition in the domestic market, and explore opportunities in overseas markets. d. Avoid white-hot competition in the domestic market and explore opportunities in overseas markets.

 IVD Market to Rely on Developing Countries for Further Growth

Ten Emerging Potential Markets Will Become the Main Direction for Domestic IVD Manufacturers to Go Overseas in the Future

Over the past decade, the competitive landscape of the IVD market in developed countries has stabilized, and in order to further develop and innovate, the major giants have begun to focus their attention on developing countries. In these countries, the government's determination to build a perfect healthcare system and the residents' demand for high-quality healthcare services are both growing, which has a great impetus to the overall development of the market. Based on the current market situation, the level of technological development, and the government's attention to the IVD market, it is expected that China, Brazil, India, Mexico, Poland, Romania, South Korea, Turkey, Vietnam, and Saudi Arabia will become the top ten emerging potential markets for future IVD manufacturers to fight for.

Insights and Reflections on the Future Development of the IVD Industry

IVD technology will realize automation advancement with TLA

Domestic IVD giants are scrambling for layout, and the competition for domestic substitution of TLA is intensifying.

The whole laboratory automation system (TLA) in the field of IVD refers to the integration of different automatic analytical instruments as well as pre-analytical and post-analytical laboratory processing devices in order to realize the integration in the laboratory, connecting them through automated conveyor rails and information networks, constituting a fully automated assembly line operating environment covering the entire inspection process and forming a large-scale automation of the whole inspection process. IVD using automated equipment and methods can make the testing process more efficient, accurate and reliable, it can be said that TLA is IVD can improve the basis of automation. At present, China's TLA market is basically monopolized by international giants, but domestic enterprises are expected to usher in new development opportunities by virtue of cost-effective and strong compatibility.

IVD industry synergy will lead industry innovation and upgrading

Co-establishment of industrial alliance to promote the high-quality development of industry technology, talent and market

In the face of the highly competitive and ever-changing IVD market, it is obvious that vendors can hardly cope with the huge waves of technology and policies by themselves. Manufacturers should actively establish long-term, close and stable comprehensive strategic cooperative relationships with medical institutions, friends, pharmaceutical companies, Internet companies, communication companies, universities and other industrial parties, in order to make great progress in the research and development, digitization, and marketization of IVDs, and to work together with the partners for mutual benefits and continuous breakthroughs in innovation, and to strengthen the basic research in the field of IVDs and the breakthroughs in the key core technologies of healthcare, in order to jointly support the development of China's IVD industry. Together, we will support the development and rise of China's IVD industry.